课题基金 / 基金详情

AN ACE INHIBITOR AS A TREATMENT FOR METHAMPHETAMINE DEPENDENCE

AN ACE INHIBITOR AS A TREATMENT FOR METHAMPHETAMINE DEPENDENCE
ACE 抑制剂治疗甲基苯丙胺依赖
批准号:
8356772
负责人:
Thomas Frederick Newton
金额:
$4.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-12-01 至 2011-11-30

项目摘要

项目成果

Thomas Frederick Newton的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ABSTRACT This will be a double-blind, placebo-controlled, between- subjects study. It will be conducted in 80 non-treatment seeking methamphetamine (MA) dependent subjects who will be resident at the Michael De Bakey VA Medical Center (MEDVAC) for the 8-day duration of the study. After admission to the study and stabilization and initial monitoring, participants will receive 15mg and 30mg MA separated by at least 4 hours. Over the next several days they will undergo testing of cue reactivity and then participate in MA self-administration in which they will have the opportunity to choose between 3mg MA or money alternatives. Participants will then be randomly assigned to placebo (n=20) or perindopril 4mg, 8mg, or 16mg (n=20 for each group) for the remainder of the study. The 15 and 30mg MA dosing, cue reactivity testing, and MA self-administration activities will then be repeated as before. Participants will then be discharged from the study and will return at intervals for payment and assessment of late emerging adverse events. Should there be difficulties securing access to sufficient hospital beds or if weekend nursing coverage becomes problematic, parts of the protocol may be conducted with participants as outpatients. Abstinence from illicit MA use will be ensured by daily urine testing with serial dilution of urine used to separate episodes of illicit use from MA administered as part of this study. Participants will receive payments of $50 per day provided they abstain from illicit MA use regardless of whether they participate as inpatients or outpatients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Triple Re-uptake Inhibitor, SKL 10406, as a New Treatment for Alcohol Dependence
  • 批准号:
    8834162
  • 项目类别:
  • 资助金额:
    $13.99万
  • 财政年份:
    2015
  • 负责人:
    Thomas Frederick Newton
  • 依托单位:
Carisbamate Treatment for Alcohol Dependence
  • 批准号:
    8735477
  • 项目类别:
  • 资助金额:
    $75.23万
  • 财政年份:
    2013
  • 负责人:
    Thomas Frederick Newton
  • 依托单位:
Carisbamate Treatment for Alcohol Dependence
  • 批准号:
    8455440
  • 项目类别:
  • 资助金额:
    $10.69万
  • 财政年份:
    2013
  • 负责人:
    Thomas Frederick Newton
  • 依托单位:
Carisbamate Treatment for Alcohol Dependence
  • 批准号:
    8900485
  • 项目类别:
  • 资助金额:
    $13.93万
  • 财政年份:
    2013
  • 负责人:
    Thomas Frederick Newton
  • 依托单位: